- Home
- PTA vs IMTX Comparison
PTA vs IMTX Comparison
Compare PTA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTA
- IMTX
- Stock Information
- Founded
- PTA 2020
- IMTX N/A
- Country
- PTA United States
- IMTX Germany
- Employees
- PTA N/A
- IMTX N/A
- Industry
- PTA Trusts Except Educational Religious and Charitable
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTA Finance
- IMTX Health Care
- Exchange
- PTA Nasdaq
- IMTX Nasdaq
- Market Cap
- PTA 1.2B
- IMTX 1.1B
- IPO Year
- PTA N/A
- IMTX N/A
- Fundamental
- Price
- PTA $19.75
- IMTX $8.17
- Analyst Decision
- PTA
- IMTX Strong Buy
- Analyst Count
- PTA 0
- IMTX 3
- Target Price
- PTA N/A
- IMTX $17.50
- AVG Volume (30 Days)
- PTA 159.2K
- IMTX 500.2K
- Earning Date
- PTA 01-01-0001
- IMTX 11-26-2024
- Dividend Yield
- PTA 8.31%
- IMTX N/A
- EPS Growth
- PTA N/A
- IMTX N/A
- EPS
- PTA N/A
- IMTX N/A
- Revenue
- PTA N/A
- IMTX $75,935,926.00
- Revenue This Year
- PTA N/A
- IMTX $54.20
- Revenue Next Year
- PTA N/A
- IMTX N/A
- P/E Ratio
- PTA N/A
- IMTX N/A
- Revenue Growth
- PTA N/A
- IMTX N/A
- 52 Week Low
- PTA $15.84
- IMTX $7.94
- 52 Week High
- PTA $19.67
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- PTA 29.73
- IMTX 24.77
- Support Level
- PTA $20.16
- IMTX $8.39
- Resistance Level
- PTA $20.68
- IMTX $8.81
- Average True Range (ATR)
- PTA 0.26
- IMTX 0.34
- MACD
- PTA -0.06
- IMTX -0.04
- Stochastic Oscillator
- PTA 15.45
- IMTX 14.89
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.